May 27, 2014 Participation in Single Use Biomanufacturing III and in PEGS Summit
On 24th April of 2014 Rentschler attended the “Single Use Biomanufacturing III: Facing the Challenges, Realising the Benefits” organized by Biochemical Engineering Special Interest Group. This conference brought together experts from the seven major single use suppliers with experienced users in the biomanufacturing industry. This year 35 specialists for single use technologies in upstream and downstream processing met there. An important topic of the conference was the automation and miniaturization in disposables for process development.
In his lecture “Opportunities and limits of disposables in DSP processes”, Dr. Stefan Schmidt, Rentschler´s Vice President DSP Production, presented the state of the technology. Rentschler’s experience for utilization of disposables for the production of material for clinical studies was demonstrated in case studies. The presentation found a great resonance in view of Rentschler’s expertise in the evaluation of leachables and extractables.
From 5th to 9th of May 2014 the 10th annual PEGS summit was held in Boston. With a record attendance of 1800+ participants from over 30 countries, attendees took advantage of the copious networking opportunities. In seven streams the participants have been informed about new large molecule therapeutics, protein expression and analysis and bioprocessing innovations. As important new market trends, the development of bispecific antibodies, antibody drug conjugates and T-cell therapies were discussed.
Also here Rentschler was represented by Dr. Stefan Schmidt, who took over various functions: He was Chairman for Process Development, discussion leader to the topic “Solving manufacturing issues of fusion proteins” and he gave a short course to “Production Challenges for Complex Biologics – ADCs, bispecifics and fusion proteins. His presentation under the heading “Benefits of Disposables in Non-Platform Manufacturing” has been followed by more than 50 visitors. Possibilities to overcome the typical difficulties of processing fusion proteins such as low titer, lack of an affinity matrix, tendency to aggregate were demonstrated in selected case studies. Especially approaches such as utilization of disposable equipment or DoE to accelerate their process development and scale up were highlighted. There was strong interest from the attendees in Rentschler’s Single Use Concept.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication